Literature DB >> 1554223

Respiratory syncytial virus infection of alveolar macrophages in adult transplant patients.

J R Panuska1, M I Hertz, H Taraf, A Villani, N M Cirino.   

Abstract

Pulmonary epithelial cells are thought to be the primary cellular targets for infection by respiratory syncytial virus (RSV) in vivo. To determine whether other pulmonary cells are infected by RSV, bronchoalveolar lavage cells from six adult transplant patients, four of whom had acute RSV infection, were examined by in situ immunohistochemistry to identify infected lung cells. Both alveolar macrophages and epithelial cells were infected with RSV in vivo. At the single-cell level, three-color immunofluorescent studies revealed that both RSV-infected epithelial cells and alveolar macrophages expressed Class II molecules of the major histocompatibility complex, but only the alveolar macrophage coexpressed interleukin-1 beta. Paraformaldehyde-fixed bronchoalveolar lavage cells from RSV-infected but not uninfected patients induced a marked proliferative response by cloned T cells indicating that in vivo infected cells expressed bioactive interleukin-1. Together, these studies indicate that the alveolar macrophage may have a critical role in the lung immune response to RSV.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1554223     DOI: 10.1164/ajrccm/145.4_Pt_1.934

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  13 in total

Review 1.  Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment.

Authors:  J B Domachowske; H F Rosenberg
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

2.  Differential expression of cytokine transcripts in neonatal and adult ovine alveolar macrophages in response to respiratory syncytial virus or toll-like receptor ligation.

Authors:  Sasha J Fach; Alicia Olivier; Jack M Gallup; Theresa E Waters; Mark R Ackermann; Howard D Lehmkuhl; Randy E Sacco
Journal:  Vet Immunol Immunopathol       Date:  2010-02-13       Impact factor: 2.046

3.  Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies.

Authors:  H B Gimenez; S Chisholm; J Dornan; P Cash
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

Review 4.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

5.  Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages. Suppression of early cytokine production and implications for incomplete immunity.

Authors:  J R Panuska; R Merolla; N A Rebert; S P Hoffmann; P Tsivitse; N M Cirino; R H Silverman; J A Rankin
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

6.  Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants.

Authors:  C Osiowy; D Horne; R Anderson
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

7.  Development of interleukin 6 and tumor necrosis factor alpha activity in nasopharyngeal secretions of infants and children during infection with respiratory syncytial virus.

Authors:  K Matsuda; H Tsutsumi; Y Okamoto; C Chiba
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

Review 8.  The Human Immune Response to Respiratory Syncytial Virus Infection.

Authors:  Clark D Russell; Stefan A Unger; Marc Walton; Jürgen Schwarze
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

9.  Stimulation of immature lung macrophages with intranasal interferon gamma in a novel neonatal mouse model of respiratory syncytial virus infection.

Authors:  Kerry M Empey; Jacob G Orend; R Stokes Peebles; Loreto Egaña; Karen A Norris; Tim D Oury; Jay K Kolls
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

10.  Efficient replication of pneumonia virus of mice (PVM) in a mouse macrophage cell line.

Authors:  Kimberly D Dyer; Ingrid Mm Schellens; Cynthia A Bonville; Brittany V Martin; Joseph B Domachowske; Helene F Rosenberg
Journal:  Virol J       Date:  2007-06-04       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.